Jump to content
World's Largest Herpes Support Group
Sign in to follow this  
effmylife

WTF is this on my Labia?! [Pic]

Recommended Posts

effmylife

I just want to preface my inquiry with this warning: After typing in various descriptions of what I saw on my labia in search engines, I found no photos to help assess this problem. I've combed through the forum for possible similarities written in the post's descriptions, but I haven't found anything that I felt were similar to what I'm seeing.

I snapped this photo of my labia and providing a link of it for various reasons: 1) to avoid describing what I'm seeing incorrectly; 2) to help any young lad sitting with these things between her legs and not seeing a photo to compare it to. It's the very reason why I'm here! If I am breaching forum rules, I truly apologize. I am not trying to be vulgar. I am seeking your expertise by providing as much information as possible. angel.gif

(NSFW: http://tinyurl.com/29pfsuz ; original photo link was too long. had to shorten it to post it.)

I'm 26 and sexually inactive for over 2 years. I've had 3 partners my entire sexual history (boyfriends, no one-nighters) and I'm baffled at what these things are on my labia. Everything down there outside of these things have been normal. Nothing burns, no irritation, no dryness, etc. Truth be told, I don't really go gallivanting down that area, so I really have no clue if this is just apart of my anatomy.

So what say you, forum? Is this normal or do I have something to worry about?

Share this post


Link to post
Share on other sites
RealisticGal

Unfortunately, it is very hard to tell you anything from a photo. First of all, most of us here are probably not trained diagnosticians. Besides, visual examination is the LEAST RELIABLE means of diagnosing herpes -- yielding about 20% incorrect results.

Problem is, herpes is a bit of a chameleon. It can look like a number of other conditions, and vice versa.

The only good way to figure this out is to be seen by a doctor, and get proper laboratory tests done to determine if you might have herpes or some other condition, or if those are just naturally occurring parts of your normal anatomy.

Are you having any other symptoms?

Share this post


Link to post
Share on other sites
Eosino

Going to the doctor would be the best thing for you. When i had my first outbreak, the doctor i saw had no idea what it was by just looking at it. It would be nice if it were that easy to identify, but sadly it's not. :(

Share this post


Link to post
Share on other sites
effmylife

Thanks, guys. I have no symptoms at all. I feel normal. :dontknow: I'm definitely heading to a GYN, but I thought I could ease my curiosity by bouncing ideas off of you guys.

I appreciate the help!

-FML

Share this post


Link to post
Share on other sites
RealisticGal

Well, sorry if we couldn't help put your mind more at ease. I have a feeling you are not dealing with herpes, but it will certainly be a good thing for you to find out what it is. Hope your gyno is able to help you figure it out.

Share this post


Link to post
Share on other sites
Forgiving1

Not sure what it could be but I'm hoping everything is ok and it can will clear up. Let us know what the docs say.

Share this post


Link to post
Share on other sites
watchmeburn

oh, wow. i have almost exactly the same thing going on down there! the first time i noticed it was when i had other symptoms and suspected herpes, but to be honest that was the first time i looked close enough to notice, since i was so concerned about everything else. i too was not sure if they had been there before.

the good news is that after being examined by 2 or 3 different doctors none of them seemed concerned with it (i think they attributed it to natural variations in everyone's physical appearance). and i tested neg for hsv 1 & 2 (IGG) at about two months, no symptoms since september, etc. anyway, i hope that helps put you at ease a bit, i guess it can't hurt to have the doc check it out if you're really curious.

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Sign in to follow this  

  • The Hive is Thriving!

    • Total Topics
      70,110
    • Total Posts
      473,852
  • Posts

    • RNY18
      https://markets.businessinsider.com/news/stocks/x-vax-technology-raises-56-million-in-upsized-series-a-financing-to-advance-lead-herpes-vaccine-program-1028376554 Add ∆gD-2 (delta gD-2) to the list ! "We believe that ∆gD-2 may be more promising than other previous vaccine candidates because it elicits a different type of immune response against HSV-1 and HSV-2 that is more effective in preclinical models at clearing virus and preventing the establishment of latency. In nonclinical models, immunization with ∆gD-2 elicits antibodies that facilitate the killing of infected cells, rapidly clearing the virus and thereby inducing sterilizing immunity," added William Jacobs, PhD, co-Inventor and Professor of Microbiology & Immunology at Albert Einstein College of Medicine."...
    • RNY18
      More X-Vax Info : https://markets.businessinsider.com/news/stocks/x-vax-technology-raises-56-million-in-upsized-series-a-financing-to-advance-lead-herpes-vaccine-program-1028376554 "We believe that ∆gD-2 may be more promising than other previous vaccine candidates because it elicits a different type of immune response against HSV-1 and HSV-2 that is more effective in preclinical models at clearing virus and preventing the establishment of latency. In nonclinical models, immunization with ∆gD-2 elicits antibodies that facilitate the killing of infected cells, rapidly clearing the virus and thereby inducing sterilizing immunity," added William Jacobs, PhD, co-Inventor and Professor of Microbiology & Immunology at Albert Einstein College of Medicine..."
    • RNY18
      They may not cure HSV but it looks like they are taking positive steps against HIV : https://timesofindia.indiatimes.com/life-style/health-fitness/he alth-news/hiv-cure-soon-human-trials-underway-in-china/articleshow/70316379.cms   "Hopefully, the second-phase trial will be completed in the latter half of 2021, and the third-phase clinical trial may start at the end of that year, which will involve thousands of volunteers in a trial to test the effectiveness of the vaccine to protect people against HIV," the researcher added."...  
    • RNY18
      Got this this morning, definitely positive news. Still seems so far off....
    • RNY18
      X-Vax Technology Raises $56 Million in Upsized Series A Financing to Advance Lead Herpes Vaccine Program A new approach to beating herpes by inducing antibodies that mediate the killing of infected cells Participants include Johnson & Johnson Innovation – JJDC, Inc. (JJDC); Adjuvant Capital, an impact investment fund supported by the Bill & Melinda Gates Foundation as an anchor investor; Serum Institute of India; Alexandria Venture Investments; Founders Fund.  JUPITER, FL, July 23, 2019. X-Vax Technology, Inc. (X-VAX), a biotechnology company developing vaccines based on a new approach that mediates the killing of infected cells, today announced that it has raised $56 million in an upsized Series A financing with participation from strategic and institutional investors, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC); Adjuvant Capital, an impact investment fund supported by the Bill & Melinda Gates Foundation as an anchor investor; Serum Institute of India; Alexandria Venture Investments; and FF DSF VI, a scout investment vehicle out of Founders Fund. Proceeds from the financing will be used to advance X-VAX’s lead program, a vaccine candidate against herpes, called ∆gD-2 (delta gD-2) for further development and production, including a Phase 1 clinical study.   “We are pleased to have the support of our new and existing investors as we continue to build our leadership position in the development of a herpes vaccine,” said Ulf Wiinberg, President and Chief Executive Officer of X-VAX. “We are encouraged by the preclinical data for our new approach to beating herpes and creating a potentially world-changing vaccine.”    “Herpes infections are a significant global health problem that affect all age groups from infants to the elderly. Infection is associated with a wide range of disease,” said Betsy Herold, MD, co-Inventor and Professor of Pediatrics, Microbiology & Immunology at Albert Einstein College of Medicine in New York. “The ability of the virus to successfully escape clearance by the immune system and to establish a non-replicating state known as latency with periodic reactivation results in lifelong infection and ongoing risk of transmission.”    “We believe that ∆gD-2 may be more promising than other previous vaccine candidates because it elicits a different type of immune response against HSV-1 and HSV-2 that is more effective in preclinical models at clearing virus and preventing the establishment of latency. In nonclinical models, immunization with ∆gD-2 elicits antibodies that facilitate the killing of infected cells, rapidly clearing the virus and thereby inducing sterilizing immunity,” added William Jacobs, PhD, co-Inventor and Professor of Microbiology & Immunology at Albert Einstein College of Medicine.   Maxim Merchant Capital, a division of Maxim Group LLC, acted as sole placement agent for the financing.   About herpes, a global epidemic There is no approved vaccine for herpes simplex. Herpes simplex virus is categorized into 2 types: herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2). More than 3.7 billion people under the age of 50 around the world are infected with HSV-1, while over 400 million have HSV-2. Neonatal infection can be devastating, at 60% fatality without treatment. Other complications include encephalitis or meningitis (inflammation of the brain or the tissue that covers the brain and spinal cord), and infectious blindness. HSV-2 is also known to contribute significantly to the spread of HIV. Antiviral drug therapy shows only moderate efficacy and comes with significant side effects. Attempts to develop an effective vaccine have repeatedly failed.   About X-Vax Technology, Inc. We are a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Our research leads us to believe that the new approach we are taking could succeed in defeating herpes. We have created a herpes vaccine candidate that we call ∆gD-2 (delta gD-2) because it is based on an HSV-2 virus genetically deleted for glycoprotein D (gD-2). With it, we have been able to prevent infections caused by herpes type 1 (HSV-1) and type 2 (HSV-2) in multiple preclinical models—with encouraging results. The vaccine induces Fc receptor activating antibodies that mediate antibody-dependent cell-mediated killing (ADCK) as the primary mechanism of protection. ADCK is induced to flag infected cells for destruction by natural immune cells.   Forward-looking statements This news release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, we are using forward-looking statements when we discuss the proposed use of proceeds from the Series A financing, when we describe our belief that our new approach to beating herpes could succeed in potentially creating a world-changing vaccine, when we discuss the belief that our vaccine candidate is more promising than other previous vaccine candidates and when we state our belief that our new approach could succeed in defeating herpes. These forward-looking statements and their implications are based on the current expectations of the management of X-VAX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation may adversely impact us inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of X-VAX to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.    Contact Andreas Eggert aeggert@x-vax.com +1-561-517-XVAX (+1-561-517-9829)   x-vax.com  
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.